Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $4,931.8M | $4,717.0M | $3,620.7M | $6,622.0M | $5,664.0M | $3,411.0M | $7,537.0M | $9,340.0M | $9,545.0M | $6,383.0M | $13.0B | $11.4B | $17.9B | $18.1B | $12.8B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, AbbVie Inc.'s last 12-month Operating Income is $13.8B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, AbbVie Inc.'s Operating Income growth was (8.2%). The average annual Operating Income growth rates for AbbVie Inc. have been 5.2% over the past three years, 16.0% over the past five years.
Over the last year, AbbVie Inc.'s Operating Income growth was (8.2%), which is lower than industry growth of 0.0%. It indicates that AbbVie Inc.'s Operating Income growth is Bad.